Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | YARS1 | P54577 | 2/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9822736 | 1.00 | SLC7A5 (0.58) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30309232 | 1.00 | SLC7A5 (0.58) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL8529219 | 1.00 | SLC7A5 (0.58) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30520377 | 0.95 | OPRD1 (0.55) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30017206 | 0.92 | OPRD1 (0.62) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30839485 | 0.92 | OPRD1 (0.64) | SLC7A5OPRD1OPRM1YARS1OPRK1 | |
| SCHEMBL31193449 | 0.92 | OPRD1 (0.52) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30839484 | 0.92 | OPRD1 (0.64) | SLC7A5OPRD1OPRM1YARS1OPRK1 | |
| SCHEMBL29823718 | 0.91 | OPRD1 (0.70) | OPRD1OPRM1MMEOPRK1 | |
| SCHEMBL22872688 | 0.90 | ERAP2 (0.52) | SLC7A5OPRD1OPRM1YARS1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12097237-B2 | Small molecule Ras inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-24 | — | — | US | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4709750-A1 | BISPECIFIC ANTI-PSEUDOMONAS ANTIBODIES WITH MODIFIED FC REGIONS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4661891-A2 | PEPTIDES FOR TREATING NEUROLOGICAL DISORDERS | Creative Bio-Peptides Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250236848-A1 | DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS | The Government of the USA as represented by the Secretary, Dept. of Health and Human Services (US) | 2025-07-24 | — | — | US | disclosed |
| US-12297502-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250109167-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-12203100-B2 | Development of dengue virus vaccine components | The Government of the USA as represented by the Secretary, Dept. of Health and Human Services (US) | 2025-01-21 | — | — | US | disclosed |
| US-20220280593-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220251521-A1 | DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS | The Government of the USA as represented by the Secretary, Dept. of Health and Human Services (US) | 2022-08-11 | — | — | US | disclosed |
| US-11332722-B2 | Development of dengue virus vaccine components | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-05-17 | — | — | US | disclosed |
| US-11312993-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022068784-A1 | SELENIUM-RICH CORDYCEPS MILITARIS DERIVED ACTIVE SELENIUM PEPTIDE WITH NEURON PROTECTION FUNCTION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 暨南大学 | 2022-04-07 | — | — | WO | disclosed |
| CN-114164134-A | Bifidobacterium longum subspecies longum with functions of preventing and relieving colitis symptoms and application thereof | 东北农业大学 | 2022-03-11 | — | — | CN | disclosed |
| US-11266709-B2 | Methods for the regulation of matrix metalloproteinase expression | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-0885899-A1 | Method for obtaining peptide fragments by use of fluorinated organic acids | SEIKO INSTRUMENTS INC. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097237-B2 | Small molecule Ras inhibitors | KRAS, HRAS, NRAS | SLC7A5 2871/4885OPRD1 4285/4885OPRM1 4514/4885 |
| US-20250109167-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | NLN, OAT, HAGH | SLC7A5 1446/4885OPRD1 3823/4885OPRM1 3263/4885 |
| US-20220280593-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | SLC7A5 414/4885OPRD1 1466/4885OPRM1 898/4885 |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | ARG2, MTPN, TNNT2 | SLC7A5 1118/4885OPRD1 4441/4885OPRM1 4686/4885 |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | SLC7A5 414/4885OPRD1 1466/4885OPRM1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.